A Phase 3 interventional study of Valbenazine in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 27 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 7th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 1 started in 2016.
This study's enrollment of 161 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
13 studies in Tardive Dyskinesia by Neurocrine Biosciences: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 3, and was the 7th registered.
Neurocrine Biosciences’s Tardive Dyskinesia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Neurocrine Biosciences’s 13 in Tardive Dyskinesia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine (NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with TD until valbenazine is anticipated to be available commercially or they complete 72 weeks of treatment. This study will allow enrollment of up to 150 medically stable male and female participants with TD who previously participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.
This study was terminated after 60 weeks due to the commercial availability of valbenazine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed dose of valbenazine administered once daily for up to 72 weeks
Drug: Valbenazine
Also known as: NBI-98854
Number of Participants Monitored for Long-term Safety of Valbenazine
Incidence of adverse events and monitoring of vital signs, clinical laboratory values, and electrocardiograms. All AEs were coded into preferred terms according to MedDRA (Medical Dictionary for Regulatory Activities) and classified by system organ class (SOC). Summaries of the incidence of all treatment-emergent AEs, treatment-related AEs, SAEs, and AEs leading to study drug discontinuation were prepared.
Time frame: 60 weeks
Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale
Clinician's perspective of the participant's overall severity of TD symptoms. The CGI-TD-Severity is based on a 7-point scale (range: 1= "Normal, not at all ill" to 7= "Among the most extremely ill patient"). A clinical response was defined as a CGI-TD-S score equal to "1" or "2."
Time frame: Baseline and Weeks 12, 24, 36, 48, and 60
Number of Participants With Clinical Response as Assessed by the Patient Satisfaction Questionnaire (PSQ)
Participant's perspective of his/her satisfaction with valbenazine treatment. The PSQ is based on a 5-point scale (range: 1=very satisfied to 5=very dissatisfied). A clinical response was defined as a PSQ score equal to "1" or "2."
Time frame: Baseline and Weeks 12, 24, 36, 48, and 60
| Milestone | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg |
|---|---|---|---|
| Started | 36 | 117 | 8 |
| Completed | 29 | 103 | 6 |
| Not completed | 7 | 14 | 2 |
Incidence of adverse events and monitoring of vital signs, clinical laboratory values, and electrocardiograms. All AEs were coded into preferred terms according to MedDRA (Medical Dictionary for Regulatory Activities) and classified by system organ class (SOC). Summaries of the incidence of all treatment-emergent AEs, treatment-related AEs, SAEs, and AEs leading to study drug discontinuation were prepared.
| Participants | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg |
|---|---|---|---|
| Number of Participants Monitored for Long-term Safety of Valbenazine | 35 | 117 | 8 |
Clinician's perspective of the participant's overall severity of TD symptoms. The CGI-TD-Severity is based on a 7-point scale (range: 1= "Normal, not at all ill" to 7= "Among the most extremely ill patient"). A clinical response was defined as a CGI-TD-S score equal to "1" or "2."
| Participants | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg |
|---|---|---|---|
| Baseline | 2 | 21 | 0 |
| Week 12 | 15 | 56 | 3 |
| Week 24 | 11 | 56 | 4 |
| Week 36 | 7 | 44 | 2 |
| Week 48 | 5 | 29 | 2 |
| Week 60 | 2 | 2 | — |
Participant's perspective of his/her satisfaction with valbenazine treatment. The PSQ is based on a 5-point scale (range: 1=very satisfied to 5=very dissatisfied). A clinical response was defined as a PSQ score equal to "1" or "2."
| Participants | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg |
|---|---|---|---|
| Baseline | 35 | 116 | 7 |
| Week 12 | 30 | 112 | 6 |
| Week 24 | 23 | 92 | 6 |
| Week 36 | 17 | 66 | 5 |
| Week 48 | 12 | 38 | 5 |
| Week 60 | 2 | 2 | — |
Collected over Up to 60 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valbenazine 40 mg | 0/35 (0%) | 3/35 (8.6%) | 6/35 (17.1%) |
| Valbenazine 80 mg | 3/117 (2.6%) | 11/117 (9.4%) | 23/117 (19.7%) |
| Valbenazine 40/80 mg | 1/8 (12.5%) | 2/8 (25%) | 6/8 (75%) |
| Event | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg |
|---|---|---|---|
| GoutMetabolism and nutrition disorders | 0/35 | 0/117 | 1/8 |
| Hypertensive heart diseaseCardiac disorders | 0/35 | 0/117 | 1/8 |
| Psychotic disorderPsychiatric disorders | 1/35 | 0/117 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 1/35 | 0/117 | 0/8 |
| Atrial fibrillationCardiac disorders | 1/35 | 0/117 | 0/8 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/35 | 1/117 | 0/8 |
| AggressionPsychiatric disorders | 0/35 | 1/117 | 0/8 |
| Non-cardiac chest painGeneral disorders | 0/35 | 1/117 | 0/8 |
| DepressionPsychiatric disorders | 0/35 | 1/117 | 0/8 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/35 | 1/117 | 0/8 |
| Event | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg |
|---|---|---|---|
| SomnolenceNervous system disorders | 1/35 | 0/117 | 5/8 |
| TremorNervous system disorders | 0/35 | 3/117 | 2/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/35 | 3/117 | 1/8 |
| Back painMusculoskeletal and connective tissue disorders | 2/35 | 4/117 | 0/8 |
| Urinary tract infectionInfections and infestations | 1/35 | 6/117 | 0/8 |
| Upper respiratory tract infectionInfections and infestations | 1/35 | 5/117 | 0/8 |
| FallInjury, poisoning and procedural complications | 1/35 | 4/117 | 0/8 |
| HeadacheNervous system disorders | 1/35 | 4/117 | 0/8 |
| Age, Continuous(years) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| Mean | 57.3 ± 8.9 | 57.9 ± 8.8 | 59.3 ± 9.0 | 57.9 ± 8.8 |
| Sex: Female, Male(Participants) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| Female | 22 | 54 | 3 | 79 |
| Male | 13 | 63 | 5 | 81 |
| Ethnicity (NIH/OMB)(Participants) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 52 | 1 | 57 |
| Not Hispanic or Latino | 31 | 65 | 7 | 103 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 14 | 30 | 3 | 47 |
| White | 21 | 86 | 4 | 111 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI) at Baseline(kg/m^2) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| Mean | 29.15 ± 5.52 | 28.54 ± 5.48 | 30.55 ± 5.29 | 28.77 ± 5.46 |
| Primary Psychiatric Diagnosis(Participants) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| Schizophrenia/schizoaffective disorder | 23 | 75 | 6 | 104 |
| Mood disorder | 12 | 42 | 2 | 56 |
| Age at Diagnosis(years) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| Schizophrenia/Schizoaffective Disorder | 27.1 ± 8.3 | 28.7 ± 11.4 | 25.3 ± 6.2 | 28.2 ± 10.6 |
| Mood Disorder | 36.0 ± 3.6 | 33.9 ± 2.1 | 46.0 ± 14.0 | 34.7 ± 1.8 |
| Tardive Dyskinesia | 48.3 ± 11.2 | 48.4 ± 9.5 | 43.8 ± 13.7 | 48.0 ± 10.1 |
| Scales(units on a scale) | Valbenazine 40 mg | Valbenazine 80 mg | Valbenazine 40/80 mg | Total |
|---|---|---|---|---|
| BPRS Score | 27.3 ± 6.3 | 26.1 ± 5.6 | 30.5 ± 9.2 | 26.6 ± 6.0 |
| CGI-TD-Severity Score | 3.9 ± 1.1 | 3.9 ± 1.3 | 4.3 ± 0.7 | 3.9 ± 1.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Jun 2017, 12 months.
Results were first posted in Dec 2018, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine